Skip to Content

Imbruvica Approval History

Imbruvica (ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft versus host disease.

Development History and FDA Approval Process for Imbruvica

Aug  2, 2017Approval FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease
Jan 19, 2017Approval U.S. FDA Approves Imbruvica (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL)
May  9, 2016Approval U.S. FDA Expands Imbruvica (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Mar  4, 2016Approval FDA Approves Imbruvica (ibrutinib) for the First-Line Treatment of Chronic Lymphocytic Leukemia
Jan 29, 2015Approval FDA Expands Approved Use of Imbruvica (ibrutinib) for Waldenström’s Macroglobulinemia
Jul 28, 2014Approval FDA Expands Approved Use of Imbruvica (ibrutinib) for Chronic Lymphocytic Leukemia
Feb 12, 2014Approval FDA Approves Imbruvica (ibrutinib) to Treat Chronic Lymphocytic Leukemia
Nov 13, 2013Approval FDA Approves Imbruvica (ibrutinib) for Mantle Cell Lymphoma
Aug 29, 2013New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA
Jul 10, 2013New Drug Application Submitted to U.S. FDA for Ibrutinib in the Treatment of Two B-Cell Malignancies
Jun 20, 2013Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published
Apr 19, 2013Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE™ and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK
Dec 11, 2012Pharmacyclics Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at American Society of Hematology (ASH) Annual Meeting
Jun  4, 2012Pharmacyclics Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at American Society of Clinical Oncology (ASCO) Annual Meeting

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.